BridgeBio Pharma, Inc. (BBIO) Stock Score, Valuation & Financial Research
BridgeBio Pharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 28/100.
Quick answer for BBIO
BridgeBio Pharma, Inc. currently has a Wall Street Score of 28/100. The stored market price is $72.44. Its financial score is 12/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What BridgeBio Pharma, Inc. does
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficien
BBIO financial snapshot
- Wall Street Score:
- 28/100
- Current price:
- $72.44
- Market capitalization:
- $14.19B
- Revenue:
- $691.8M
- Net income:
- $-696.2M
- Free cash flow:
- $-447.0M
- Cash:
- $677.9M
- Total debt:
- $2.49B
- EPS:
- -3.58
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 41/100
What stands out
- Reported year-over-year revenue growth is +0.4%.
- Free cash flow is $-447.0M, showing cash burn in the current stored period.
- The balance sheet shows $677.9M of cash versus $2.49B of total debt, so leverage deserves attention.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BBIO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.